Edition:
United States

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

25.43USD
4:00pm EDT
Change (% chg)

$0.54 (+2.17%)
Prev Close
$24.89
Open
$24.63
Day's High
$26.01
Day's Low
$24.48
Volume
185,062
Avg. Vol
179,209
52-wk High
$29.80
52-wk Low
$7.37

Select another date:

Mon, Mar 19 2018

BRIEF-Collegium Appoints Shirley Kuhlmann As General Counsel

* COLLEGIUM ANNOUNCES THE APPOINTMENT OF SHIRLEY KUHLMANN AS GENERAL COUNSEL Source text for Eikon: Further company coverage:

BRIEF-Collegium Reports Q4 Loss Per Share $0.54

* COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Collegium To Host Conference Call To Discuss Fourth Quarter 2017 Financial Results And Provide Corporate Update

* COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA

* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

BRIEF-Collegium reports third quarter loss of $0.45 per share

* Collegium reports third quarter financial results and provides corporate update

Select another date: